An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Guardant Health, a leading precision oncology company, will report its first quarter 2024 financial results on May 9, 2024, after market close. The company's management will host a webcasted conference call, providing investors with an opportunity to listen to the live audio on the company's website. The webcast will also be available for replay after the event.
Guardant Health, un'azienda leader in oncologia di precisione, comunicherà i risultati finanziari del primo trimestre del 2024 il 9 maggio 2024, dopo la chiusura del mercato. La direzione dell'azienda ospiterà una conferenza telefonica trasmessa via web, offrendo agli investitori la possibilità di ascoltare l'audio dal vivo sul sito web dell'azienda. La webcast sarà disponibile anche per la riproduzione successiva all'evento.
Guardant Health, una empresa líder en oncología de precisión, reportará sus resultados financieros del primer trimestre de 2024 el 9 de mayo de 2024, después del cierre del mercado. La gestión de la empresa presentará una conferencia telefónica retransmitida en la web, proporcionando a los inversores la oportunidad de escuchar el audio en vivo en el sitio web de la empresa. La transmisión web también estará disponible para su reproducción después del evento.
정밀 종양학 분야의 선도 기업인 Guardant Health는 2024년 5월 9일 시장 마감 후 2024년도 1분기 재무 결과를 보고할 예정입니다. 회사 경영진은 웹캐스트된 전화 회의를 주최하여 투자자들이 회사 웹사이트에서 실시간 오디오를 들을 수 있는 기회를 제공할 것입니다. 이 웹캐스트는 행사 후에도 재생을 위해 사용할 수 있습니다.
Guardant Health, une entreprise leader en oncologie de précision, publiera ses résultats financiers du premier trimestre 2024 le 9 mai 2024, après la fermeture du marché. La direction de l'entreprise organisera une conférence téléphonique diffusée en webcast, offrant aux investisseurs l'opportunité d'écouter l'audio en direct sur le site web de l'entreprise. Le webcast sera également disponible en replay après l'événement.
Guardant Health, ein führendes Unternehmen in der Präzisionsonkologie, wird am 9. Mai 2024 nach Börsenschluss seine Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Management des Unternehmens wird einen per Webcast übertragenen Konferenzanruf veranstalten, der den Investoren die Möglichkeit bietet, das Live-Audio auf der Website des Unternehmens zu hören. Der Webcast wird nach der Veranstaltung auch zur Wiederholung verfügbar sein.
Positive
None.
Negative
None.
PALO ALTO, Calif.--(BUSINESS WIRE)--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.
About Guardant Health
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.
